Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong(Cedars-Sinai Medical Center), Ravi Salgia(City Of Hope National Medical Center)
Cited by 1,315
Related Papers
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
|Journal of Clinical Oncology|2011|551
c-Met Overexpression Is a Prognostic Factor in Ovarian Cancer and an Effective Target for Inhibition of Peritoneal Dissemination and Invasion
|Cancer Research|2007|260
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
|Journal for ImmunoTherapy of Cancer|2018|190
c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma
|Clinical Cancer Research|2007|154